Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bilirubin is an orange-yellow linear tetrapyrrole compound produced during normal breakdown of heme from senescent red blood cells. Heme degradation occurs primarily via macrophages where heme oxygenase converts heme into biliverdin which is then reduced to unconjugated (indirect) bilirubin by biliverdin reductase. Unconjugated bilirubin circulates bound tightly to albumin due to its hydrophobicity until taken up by hepatocytes where it undergoes conjugation with glucuronic acid via UDP-glucuronosyltransferase making it water-soluble ("direct"/conjugated). Conjugated bilirubin enters bile and ultimately reaches the intestine where bacterial enzymes further metabolize it into urobilinogen/stercobilinogen which are excreted through feces or urine after partial reabsorption. Clinically significant elevations occur when production exceeds hepatic clearance capacity—as seen with hemolysis—or when hepatic uptake/conjugation/excretion pathways are impaired—as seen with liver diseases or genetic disorders affecting conjugating enzymes. Elevated serum/plasma total and fractioned (direct/indirect) bilirubins serve as key diagnostic markers for jaundice etiology evaluation across all ages. While some studies suggest mild hyperbilirubinemia may confer antioxidant benefits under certain conditions without underlying liver pathology, excessive accumulation—particularly unbound/unconjugated form—is highly toxic especially during early brain development leading potentially irreversible neurological damage if untreated. Treatment strategies focus on enhancing elimination rather than directly inhibiting/binding the molecule.
Not applicable—no drugs act on bilirubin as their primary mechanism. Phototherapy acts physically by converting unconjugated bilirubin into excretable forms via light-induced structural changes rather than biochemical targeting of the molecule itself.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bilirubin.